Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Jun 09, 2018 9:07pm

270 Views

Post# 28150717

RE:$3 Billion for ANTIBE

ATE would see value in doing a share consolidation this year to get extensive exposure to institutional capital. Would management have a target of o/s shares they would prefer for the Nasdaq, considering a suggested varying SC ratio from 5:1 to 10:1? Listing on the Nasdaq with share consolidation seems to be the thing to do; better exposure to US investors and larger available capital focused to healthcare....here are recent listings moved to the Nasdaq......

IMV shares o/s 43m SC 3.2 to 1 May 3 5.11 now 6.05 high 7.21

ONC shares o/s 16m SC 9.5 to 1 May 25 9.03 now 9.04 high 10.57

Bullboard Posts

Global Tungsten Market and Supply Security